Last week, Novartis A.G. (NYSE: NVS) announced a huge $8.7 billion all-cash purchase of AveXis Inc.(NASDAQ: AVXS), and many on Wall Street think there is a good chance that mergers and acquisitions continue in the biotech space. Many of the large companies are flush with cash, and with interest rates still historically low, floating debt to fund purchases still makes sense as well.
Why 4 Top Biotech Stocks May Be the Next Takeover Targets
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться